A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.

Luis TeixeiraJacques MedioniJulie GaribalOlivier AdoteviLudovic DoucetMarie-Agnès Dragon DureyZineb GhriebJean-Jacques KiladjianMara BrizardCaroline LaheurteMaria WehbeElodie PliquetMarie EscandeRémy DefranceStephane CulineStephane OudardSimon Wain-HobsonValérie DopplerThierry HuetPierre Langlade-Demoyen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

INVAC-1 vaccination was safe, well tolerated, and immunogenic when administered intradermally at the three tested doses in patients with relapsed or refractory cancers. Disease stabilization was observed for the majority of patients (58%) during the treatment period and beyond.See related commentary by Slingluff Jr, p. 529.

Keyphrases

endothelial cells
ejection fraction
induced pluripotent stem cells
acute lymphoblastic leukemia
prognostic factors
acute myeloid leukemia
diffuse large b cell lymphoma
cell free
single molecule
patient reported outcomes
combination therapy
patient reported
replacement therapy